Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical Characterization

Overview

Journal Neurology

Specialty Neurology

Date 2010 Jan 1

PMID 20042704

Citations 1023

Authors

R C Petersen

P S Aisen

L A Beckett

M C Donohue

A C Gamst

D J Harvey

C R Jack Jr

W J Jagust

L M Shaw

A W Toga

J Q Trojanowski

M W Weiner

Affiliations

Soon will be listed here.

Abstract

Background: Neuroimaging measures and chemical biomarkers may be important indices of clinical progression in normal aging and mild cognitive impairment (MCI) and need to be evaluated longitudinally.

Objective: To characterize cross-sectionally and longitudinally clinical measures in normal controls, subjects with MCI, and subjects with mild Alzheimer disease (AD) to enable the assessment of the utility of neuroimaging and chemical biomarker measures.

Methods: A total of 819 subjects (229 cognitively normal, 398 with MCI, and 192 with AD) were enrolled at baseline and followed for 12 months using standard cognitive and functional measures typical of clinical trials.

Results: The subjects with MCI were more memory impaired than the cognitively normal subjects but not as impaired as the subjects with AD. Nonmemory cognitive measures were only minimally impaired in the subjects with MCI. The subjects with MCI progressed to dementia in 12 months at a rate of 16.5% per year. Approximately 50% of the subjects with MCI were on antidementia therapies. There was minimal movement on the Alzheimer's Disease Assessment Scale-Cognitive Subscale for the normal control subjects, slight movement for the subjects with MCI of 1.1, and a modest change for the subjects with AD of 4.3. Baseline CSF measures of Abeta-42 separated the 3 groups as expected and successfully predicted the 12-month change in cognitive measures.

Conclusion: The Alzheimer's Disease Neuroimaging Initiative has successfully recruited cohorts of cognitively normal subjects, subjects with mild cognitive impairment (MCI), and subjects with Alzheimer disease with anticipated baseline characteristics. The 12-month progression rate of MCI was as predicted, and the CSF measures heralded progression of clinical measures over 12 months.

Citing Articles

An experimental framework for conjoint measures of olfaction, navigation, and motion as pre-clinical biomarkers of Alzheimer's disease.

Biljman K, Gozes I, Lam J, Li V J Alzheimers Dis Rep. 2025; 8(1):1722-1744.

PMID: 40034341 PMC: 11863766. DOI: 10.1177/25424823241307617.

Deciphering novel mitochondrial signatures: multi-omics analysis uncovers cross-disease markers and oligodendrocyte pathways in Alzheimer's disease and glioblastoma.

Xu X, Wang J, Chen T, Wang S, Wang F, He J Front Aging Neurosci. 2025; 17:1536142.

PMID: 40018519 PMC: 11865232. DOI: 10.3389/fnagi.2025.1536142.

Impact of the polygenic risk scores for attention-deficit/hyperactivity disorder in Alzheimer's disease.

Leffa D, Povala G, Bellaver B, Ferrari-Souza J, Ferreira P, Lussier F Alzheimers Dement. 2025; 21(2):e70003.

PMID: 39998851 PMC: 11853731. DOI: 10.1002/alz.70003.

Individual bioenergetic capacity as a potential source of resilience to Alzheimer's disease.

Arnold M, Buyukozkan M, Doraiswamy P, Nho K, Wu T, Gudnason V Nat Commun. 2025; 16(1):1910.

PMID: 39994231 PMC: 11850607. DOI: 10.1038/s41467-025-57032-0.

Advancing Precision Oncology Through Modeling of Longitudinal and Multimodal Data.

Zhuang L, Park S, Skates S, Prosper A, Aberle D, Hsu W ArXiv. 2025; .

PMID: 39990791 PMC: 11844620.

References

Gauthier S, Reisberg B, Zaudig M, Petersen R, Ritchie K, Broich K . Mild cognitive impairment. Lancet. 2006; 367(9518):1262-70. DOI: 10.1016/S0140-6736(06)68542-5. View

Petersen R . Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004; 256(3):183-94. DOI: 10.1111/j.1365-2796.2004.01388.x. View

Petersen R, Smith G, Waring S, Ivnik R, Tangalos E, Kokmen E . Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999; 56(3):303-8. DOI: 10.1001/archneur.56.3.303. View

Hachinski V, Iliff L, Zilhka E, DU BOULAY G, McAllister V, Marshall J . Cerebral blood flow in dementia. Arch Neurol. 1975; 32(9):632-7. DOI: 10.1001/archneur.1975.00490510088009. View

Laird N, Ware J . Random-effects models for longitudinal data. Biometrics. 1982; 38(4):963-74. View

Jicha G, Parisi J, Dickson D, Johnson K, Cha R, Ivnik R . Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol. 2006; 63(5):674-81. DOI: 10.1001/archneur.63.5.674. View

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E . Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984; 34(7):939-44. DOI: 10.1212/wnl.34.7.939. View

Jack Jr C, Petersen R, Xu Y, OBrien P, Smith G, Ivnik R . Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999; 52(7):1397-403. PMC: 2730146. DOI: 10.1212/wnl.52.7.1397. View

Petersen R, Parisi J, Dickson D, Johnson K, Knopman D, Boeve B . Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol. 2006; 63(5):665-72. DOI: 10.1001/archneur.63.5.665. View

10.

Hardy J . Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 1997; 20(4):154-9. DOI: 10.1016/s0166-2236(96)01030-2. View

11.

Thal L, Ferris S, Kirby L, Block G, Lines C, Yuen E . A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. 2005; 30(6):1204-15. DOI: 10.1038/sj.npp.1300690. View

12.

Petersen R, Thomas R, Grundman M, Bennett D, Doody R, Ferris S . Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005; 352(23):2379-88. DOI: 10.1056/NEJMoa050151. View

13.

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L . Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006; 5(3):228-34. DOI: 10.1016/S1474-4422(06)70355-6. View

14.

Shaw L, Korecka M, Clark C, Lee V, Trojanowski J . Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov. 2007; 6(4):295-303. DOI: 10.1038/nrd2176. View

15.

Feldman H, Ferris S, Winblad B, Sfikas N, Mancione L, He Y . Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol. 2007; 6(6):501-12. DOI: 10.1016/S1474-4422(07)70109-6. View

16.

ROSEN W, Mohs R, Davis K . A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984; 141(11):1356-64. DOI: 10.1176/ajp.141.11.1356. View

17.

Cummings J, Mega M, Gray K, Carusi D, Gornbein J . The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994; 44(12):2308-14. DOI: 10.1212/wnl.44.12.2308. View

18.

Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock G, Truyen L . Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology. 2008; 70(22):2024-35. DOI: 10.1212/01.wnl.0000303815.69777.26. View

19.

Yesavage J, Brink T, Rose T, Lum O, Huang V, Adey M . Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982; 17(1):37-49. DOI: 10.1016/0022-3956(82)90033-4. View